01 Increasing Development of Disease-Modifying Therapies The neurodegenerative disease market is increasingly shifting toward therapies designed to target the underlying biological mechanisms of disease progression rather than focusing only on symptomatic relief. Pharmaceutical and biotechnology companies are investing in novel therapeutic approaches for conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. This trend is supporting the development of treatments aimed at slowing disease progression and improving long-term patient outcomes. In March 2025, pharmaceutical and biotechnology companies continued advancing research and development programs focused on disease-modifying therapies for neurodegenerative disorders.
02 Growing Adoption of Biomarker-Based Diagnosis and Patient Stratification Biomarkers are playing an increasingly important role in the diagnosis, assessment, and management of neurodegenerative diseases. Advanced imaging, blood-based biomarkers, genetic testing, and other diagnostic approaches can support earlier disease identification and help classify patients according to specific disease characteristics. This trend is improving clinical research and supporting more precise approaches to patient selection and treatment development. In July 2025, neuroscience researchers continued advancing biomarker-based approaches to support earlier detection, disease assessment, and patient stratification in neurodegenerative disorders.
01 Rising Global Aging Population and Increasing Disease Prevalence The growing global elderly population is increasing the prevalence of age-associated neurodegenerative conditions. Disorders such as Alzheimer's disease and Parkinson's disease become more common with advancing age, creating greater demand for diagnosis, treatment, and long-term disease management. The increasing disease burden associated with population aging is therefore a fundamental driver of the neurodegenerative disease market.
01 High Cost of Advanced Therapies and Long-Term Disease Management Neurodegenerative diseases often require prolonged medical treatment, continuous monitoring, specialized healthcare services, and long-term patient support. Advanced therapies and diagnostic procedures can also involve substantial costs, creating financial pressure on patients and healthcare systems. These affordability and resource challenges can limit access to advanced treatment options.
01 Expansion of Specialized Neurology Care and Treatment Infrastructure Growing investment in specialized neurological care centers, memory clinics, research institutions, and diagnostic facilities is creating opportunities within the neurodegenerative disease market. Improved access to specialized healthcare infrastructure can support earlier diagnosis, better disease management, and wider availability of advanced treatment options. The expansion of dedicated neurology and neuroscience infrastructure therefore represents an important market opportunity.
01 Complex Disease Biology and Difficulty in Clinical Drug Development Neurodegenerative diseases involve complex biological mechanisms and can progress differently among individual patients. This variability creates difficulties in understanding disease pathways, selecting appropriate clinical trial participants, and accurately evaluating treatment effectiveness. The high complexity of disease biology and the challenges associated with successful drug development remain significant obstacles for companies operating in the neurodegenerative disease market.
March 2026 Biogen expanded its neuroscience portfolio with continued advancements in therapies and research programs targeting neurodegenerative disorders, including Alzheimer’s disease and other neurological conditions.
September 2025 Eli Lilly expanded its neuroscience pipeline with innovative treatment developments focused on neurodegenerative diseases and improving patient outcomes.
May 2025 Roche strengthened its neurology portfolio with ongoing research and development initiatives focused on disease-modifying therapies for neurodegenerative conditions.